Compare · AVNS vs EW
AVNS vs EW
Side-by-side comparison of Avanos Medical Inc. (AVNS) and Edwards Lifesciences Corporation (EW): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AVNS and EW operate in Industrial Specialties (Health Care), so they compete in similar markets.
- EW is the larger of the two at $52.38B, about 44.7x AVNS ($1.17B).
- EW has been more active in the news (3 items in the past 4 weeks vs 1 for AVNS).
- EW has more recent analyst coverage (25 ratings vs 7 for AVNS).
- Company
- Avanos Medical Inc.
- Edwards Lifesciences Corporation
- Price
- $24.99+0.04%
- $90.83+0.31%
- Market cap
- $1.17B
- $52.38B
- 1M return
- -
- +9.41%
- 1Y return
- -
- +11.74%
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NYSE
- NYSE
- IPO
- 2014
- News (4w)
- 1
- 3
- Recent ratings
- 7
- 25
Avanos Medical Inc.
Avanos Medical, Inc. operates as a medical technology company that focuses on delivering medical device solutions to improve patients' quality of life in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions; and respiratory health products, such as closed airway suction systems and other airway management devices under the Ballard, Microcuff, and Endoclear brands. The company also provides a portfolio of non-opioid pain solutions, including acute pain products, such as On-Q and ambIT surgical pain pumps and Game Ready cold and compression therapy systems; and interventional pain solutions, which offers minimally invasive pain relieving therapies, such as Coolief pain relief therapy. It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.
Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral regurgitation, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products, oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Latest AVNS
- SEC Form 15-12G filed by Avanos Medical Inc.
- SEC Form S-8 POS filed by Avanos Medical Inc.
- Avanos Medical Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financial Obligation, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits
- SVP, Operations Delgado Sigfrido returned $2,765,675 worth of shares to the company (110,627 units at $25.00) and was granted 54,886 shares, closing all direct ownership in the company (SEC Form 4) (tax liability)
- SVP, Chief Financial Officer Galovan Scott Michael returned $5,792,925 worth of shares to the company (231,717 units at $25.00) and was granted 96,121 shares, closing all direct ownership in the company (SEC Form 4) to satisfy tax liability
- Chief Executive Officer Pacitti David returned $19,173,100 worth of shares to the company (766,924 units at $25.00) and was granted 444,730 shares, closing all direct ownership in the company (SEC Form 4) (tax liability)
- Director Shimer Julie Ann returned $1,252,250 worth of shares to the company (50,090 units at $25.00), closing all direct ownership in the company (SEC Form 4) to cover taxes
- Director Oleary Patrick J returned $1,366,000 worth of shares to the company (54,640 units at $25.00), closing all direct ownership in the company (SEC Form 4) (for tax liability)
- Director Franchini Indrani Lall returned $120,425 worth of shares to the company (4,817 units at $25.00), closing all direct ownership in the company (SEC Form 4) (for withholding tax)
- Director Egbuonu-Davis Lisa returned $345,275 worth of shares to the company (13,811 units at $25.00), closing all direct ownership in the company (SEC Form 4) (for tax liability)
Latest EW
- CVP, TAVR Lippis Daniel J. exercised 619 shares at a strike of $72.68 and sold $56,967 worth of shares (619 units at $92.03) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form S-8 filed by Edwards Lifesciences Corporation
- SEC Form 10-Q filed by Edwards Lifesciences Corporation
- CVP, JAPAC Markowitz Wayne sold $12,588 worth of shares (146 units at $86.03), decreasing direct ownership by 0.67% to 21,534 units (SEC Form 4)
- CVP, JAPAC Markowitz Wayne exercised 9,628 shares at a strike of $74.02 and sold $818,958 worth of shares (9,628 units at $85.06) (SEC Form 4)
- UBS initiated coverage on Edwards Lifesciences with a new price target
- CEO Zovighian Bernard J gifted 320 shares, received a gift of 320 shares and sold $245,134 worth of shares (2,921 units at $83.93), decreasing direct ownership by 0.32% to 98,845 units (SEC Form 4)
- Edwards Lifesciences upgraded by Leerink Partners with a new price target
- Edwards Lifesciences Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Edwards Lifesciences Reports Second Quarter Results